Follow
Maria Corinna Palanca-Wessels
Maria Corinna Palanca-Wessels
Verified email at u.washington.edu
Title
Cited by
Cited by
Year
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ...
New England Journal of Medicine 382 (7), 597-609, 2020
10342020
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ...
The Lancet 390 (10094), 555-566, 2017
5482017
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
ED Jacobsen, JP Sharman, Y Oki, RH Advani, JN Winter, CM Bello, ...
Blood, The Journal of the American Society of Hematology 125 (9), 1394-1402, 2015
3112015
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a …
MCA Palanca-Wessels, M Czuczman, G Salles, S Assouline, LH Sehn, ...
The Lancet Oncology 16 (6), 704-715, 2015
3082015
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
M Pfeifer, B Zheng, T Erdmann, H Koeppen, R McCord, M Grau, A Staiger, ...
Leukemia 29 (7), 1578-1586, 2015
1532015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
A Forero-Torres, B Holkova, J Goldschmidt, R Chen, G Olsen, RV Boccia, ...
Blood, The Journal of the American Society of Hematology 126 (26), 2798-2804, 2015
1482015
Genetic analysis of long-term Barrett's esophagus epithelial cultures exhibiting cytogenetic and ploidy abnormalities
MC Palanca-Wessels, MT Barrett, PC Galipeau, KL Rohrer, BJ Reid, ...
Gastroenterology 114 (2), 295-304, 1998
1021998
Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett’s esophagus
MT Barrett, D Pritchard, C Palanca-Wessels, J Anderson, BJ Reid, ...
Cancer research 63 (14), 4211-4217, 2003
922003
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model
MCA Palanca-Wessels, A Klingelhutz, BJ Reid, TH Norwood, KE Opheim, ...
Carcinogenesis 24 (7), 1183-1190, 2003
752003
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells
MC Palanca-Wessels, AJ Convertine, R Cutler-Strom, GC Booth, F Lee, ...
Molecular Therapy 19 (8), 1529-1537, 2011
732011
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells
MC Palanca-Wessels, GC Booth, AJ Convertine, BB Lundy, GY Berguig, ...
Oncotarget 7 (8), 9561, 2016
542016
Mutants of the Agrobacterium tumefaciens virA gene exhibiting acetosyringone-independent expression of the vir regulon
RG Ankenbauer, EA Best, CA Palanca, EW Nester
Mol. Plant-Microbe Interact 4, 400-406, 1991
541991
Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry
NL Bartlett, MR Smith, T Siddiqi, RH Advani, OA O’Connor, JP Sharman, ...
Leukemia & Lymphoma 58 (7), 1607-1616, 2017
522017
Advances in the treatment of hematologic malignancies using immunoconjugates
MC Palanca-Wessels, OW Press
Blood, The Journal of the American Society of Hematology 123 (15), 2293-2301, 2014
502014
Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody–polymer conjugate
GY Berguig, AJ Convertine, J Shi, MC Palanca-Wessels, CL Duvall, ...
Molecular pharmaceutics 9 (12), 3506-3514, 2012
452012
Intracellular delivery system for antibody–peptide drug conjugates
GY Berguig, AJ Convertine, S Frayo, HB Kern, E Procko, D Roy, ...
Molecular therapy 23 (5), 907-917, 2015
422015
Improving the efficacy of radioimmunotherapy for non‐Hodgkin lymphomas
MCA Palanca‐Wessels, OW Press
Cancer 116 (S4), 1126-1133, 2010
372010
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
YH Kim, HM Prince, S Whittaker, SM Horwitz, M Duvic, O Bechter, ...
European Journal of Cancer 148, 411-421, 2021
352021
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
JH Strickler, K Ng, A Cercek, C Fountzilas, FA Sanchez, JM Hubbard, ...
Journal of Clinical Oncology 39 (3_suppl), TPS153-TPS153, 2021
342021
A phase I study of the anti-CD79b antibody-drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
MC Palanca-Wessels, IW Flinn, LH Sehn, M Patel, R Sangha, ...
Blood 120 (21), 56, 2012
302012
The system can't perform the operation now. Try again later.
Articles 1–20